These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
437 related items for PubMed ID: 25475745
1. Soluble Klotho Protects against Uremic Cardiomyopathy Independently of Fibroblast Growth Factor 23 and Phosphate. Xie J, Yoon J, An SW, Kuro-o M, Huang CL. J Am Soc Nephrol; 2015 May; 26(5):1150-60. PubMed ID: 25475745 [Abstract] [Full Text] [Related]
2. Deficiency of Soluble α-Klotho as an Independent Cause of Uremic Cardiomyopathy. Xie J, Wu YL, Huang CL. Vitam Horm; 2016 May; 101():311-30. PubMed ID: 27125747 [Abstract] [Full Text] [Related]
3. Klotho and phosphate are modulators of pathologic uremic cardiac remodeling. Hu MC, Shi M, Cho HJ, Adams-Huet B, Paek J, Hill K, Shelton J, Amaral AP, Faul C, Taniguchi M, Wolf M, Brand M, Takahashi M, Kuro-O M, Hill JA, Moe OW. J Am Soc Nephrol; 2015 Jun; 26(6):1290-302. PubMed ID: 25326585 [Abstract] [Full Text] [Related]
7. Association between FGF23, α-Klotho, and Cardiac Abnormalities among Patients with Various Chronic Kidney Disease Stages. Tanaka S, Fujita S, Kizawa S, Morita H, Ishizaka N. PLoS One; 2016 Jun; 11(7):e0156860. PubMed ID: 27400031 [Abstract] [Full Text] [Related]
8. Klotho and Clinical Outcomes in CKD: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study. Edmonston D, Fuchs MAA, Burke EJ, Isakova T, Wolf M, Chronic Renal Insufficiency Cohort (CRIC) Study Investigators. Am J Kidney Dis; 2024 Sep; 84(3):349-360.e1. PubMed ID: 38583756 [Abstract] [Full Text] [Related]
9. Soluble α-klotho and heparin modulate the pathologic cardiac actions of fibroblast growth factor 23 in chronic kidney disease. Yanucil C, Kentrup D, Campos I, Czaya B, Heitman K, Westbrook D, Osis G, Grabner A, Wende AR, Vallejo J, Wacker MJ, Navarro-Garcia JA, Ruiz-Hurtado G, Zhang F, Song Y, Linhardt RJ, White K, Kapiloff MS, Faul C. Kidney Int; 2022 Aug; 102(2):261-279. PubMed ID: 35513125 [Abstract] [Full Text] [Related]
10. Plasmatic Klotho and FGF23 Levels as Biomarkers of CKD-Associated Cardiac Disease in Type 2 Diabetic Patients. Silva AP, Mendes F, Carias E, Gonçalves RB, Fragoso A, Dias C, Tavares N, Café HM, Santos N, Rato F, Leão Neves P, Almeida E. Int J Mol Sci; 2019 Mar 27; 20(7):. PubMed ID: 30934737 [Abstract] [Full Text] [Related]
11. Randomized Clinical Trial of Sevelamer Carbonate on Serum Klotho and Fibroblast Growth Factor 23 in CKD. Liabeuf S, Ryckelynck JP, El Esper N, Ureña P, Combe C, Dussol B, Fouque D, Vanhille P, Frimat L, Thervet E, Mentaverri R, Prié D, Choukroun G, FRENCH Study collaborators. Clin J Am Soc Nephrol; 2017 Dec 07; 12(12):1930-1940. PubMed ID: 29074818 [Abstract] [Full Text] [Related]
12. The anti-aging factor Klotho protects against acquired long QT syndrome induced by uremia and promoted by fibroblast growth factor 23. Navarro-García JA, Salguero-Bodes R, González-Lafuente L, Martín-Nunes L, Rodríguez-Sánchez E, Bada-Bosch T, Hernández E, Mérida-Herrero E, Praga M, Solís J, Arribas F, Bueno H, Kuro-O M, Fernández-Velasco M, Ruilope LM, Delgado C, Ruiz-Hurtado G. BMC Med; 2022 Jan 19; 20(1):14. PubMed ID: 35042527 [Abstract] [Full Text] [Related]
13. Soluble klotho and autosomal dominant polycystic kidney disease. Pavik I, Jaeger P, Ebner L, Poster D, Krauer F, Kistler AD, Rentsch K, Andreisek G, Wagner CA, Devuyst O, Wüthrich RP, Schmid C, Serra AL. Clin J Am Soc Nephrol; 2012 Feb 19; 7(2):248-57. PubMed ID: 22193235 [Abstract] [Full Text] [Related]
15. Serum levels of soluble secreted α-Klotho are decreased in the early stages of chronic kidney disease, making it a probable novel biomarker for early diagnosis. Shimamura Y, Hamada K, Inoue K, Ogata K, Ishihara M, Kagawa T, Inoue M, Fujimoto S, Ikebe M, Yuasa K, Yamanaka S, Sugiura T, Terada Y. Clin Exp Nephrol; 2012 Oct 19; 16(5):722-9. PubMed ID: 22457086 [Abstract] [Full Text] [Related]
16. Adiponectin alters renal calcium and phosphate excretion through regulation of klotho expression. Rutkowski JM, Pastor J, Sun K, Park SK, Bobulescu IA, Chen CT, Moe OW, Scherer PE. Kidney Int; 2017 Feb 19; 91(2):324-337. PubMed ID: 27914707 [Abstract] [Full Text] [Related]
17. [Correlations of FGF23 and Klotho with cardiovascular injury in chronic kidney disease patients]. Gan L, Zhou Q. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2017 Sep 28; 42(9):1058-1065. PubMed ID: 28989152 [Abstract] [Full Text] [Related]
18. Fibroblast growth factor 23 is not associated with and does not induce arterial calcification. Scialla JJ, Lau WL, Reilly MP, Isakova T, Yang HY, Crouthamel MH, Chavkin NW, Rahman M, Wahl P, Amaral AP, Hamano T, Master SR, Nessel L, Chai B, Xie D, Kallem RR, Chen J, Lash JP, Kusek JW, Budoff MJ, Giachelli CM, Wolf M, Chronic Renal Insufficiency Cohort Study Investigators. Kidney Int; 2013 Jun 28; 83(6):1159-68. PubMed ID: 23389416 [Abstract] [Full Text] [Related]
19. The intersection of mineralocorticoid receptor activation and the FGF23-Klotho cascade: a duopoly that promotes renal and cardiovascular injury. Epstein M, Freundlich M. Nephrol Dial Transplant; 2022 Jan 25; 37(2):211-221. PubMed ID: 34459924 [Abstract] [Full Text] [Related]
20. [Potential application of fibroblast growth factor 23-klotho axis in chronic kidney disease]. Lacroix JS, Urena-Torres P. Nephrol Ther; 2020 Mar 25; 16(2):83-92. PubMed ID: 31843356 [Abstract] [Full Text] [Related] Page: [Next] [New Search]